机构:[1]Department of Hepatobiliary Surgery, The First People’s Hospital of Kunming City & Galmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China[2]Department of Hepatobiliary Surgery, Da Ban Qiao Township Public Health Center of Guandu District, Kunming, Yunnan, China
This study is supported by The Joint Special Project Spon-sored by Science and Technology Department of Yunnan Provinceand Kunming Medical University, Postdoctoral Fellow SpecialProject of The First People’s Hospital of Kunming City, The Foun-dation for Outstanding Young Scientist in Kunming City, TheTen-Hundred-Thousand Project and The Foundation for Clinical Experts Sponsored by Kunming Municipal Health and Plan-ning Commission, Yunnan Province Applied Basic Research (No.2017FE468(-099)), and Health Technology Project of YunnanProvince (2018NS0162 and 2017NS080).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类|4 区医学
小类|4 区胃肠肝病学
最新[2025]版:
大类|3 区医学
小类|4 区胃肠肝病学
第一作者:
第一作者机构:[1]Department of Hepatobiliary Surgery, The First People’s Hospital of Kunming City & Galmette Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
通讯作者:
推荐引用方式(GB/T 7714):
Hu Zongqiang,Li Li,Ran Jianghua,et al.miR-125b acts as anti-fibrotic therapeutic target through regulating Gli3 in vivo and in vitro.[J].Annals of hepatology.2019,18(6):825-832.doi:10.1016/j.aohep.2019.06.016.
APA:
Hu Zongqiang,Li Li,Ran Jianghua,Chu Guang,Gao Hongqiang...&Chen Jiapeng.(2019).miR-125b acts as anti-fibrotic therapeutic target through regulating Gli3 in vivo and in vitro..Annals of hepatology,18,(6)
MLA:
Hu Zongqiang,et al."miR-125b acts as anti-fibrotic therapeutic target through regulating Gli3 in vivo and in vitro.".Annals of hepatology 18..6(2019):825-832